BioSpace News Archive

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T ® product candidate that incorporates the company’s iMC activation and CaspaCIDe ® safety switc

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Inspyr Therapeutics, Inc., a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces it continues to strengthen its global intellectual property portfolio of adenosine receptor antagonists.

Thermo Fisher Scientific announced today the availability of a new direct from saliva PCR test for COVID-19 to enable widespread, high-frequency surveillance testing.

Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform.

L7 Informatics announced that it has partnered with Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, to deploy L7|ESP (Enterprise Science Platform) and implement an integrated manufacturing and lab system. Specifically, L7 will provide Cognate BioServices with a unified data and

The winner of this year’s SwedenBIO Award was announced on Wednesday December 9th. Calliditas Therapeutics AB received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-line results at week 48 from the phase 3 PEGASUS study, which demonstrated sustained haematological and clinical improvements in patients with paroxysmal nocturnal haemoglobinuria (PNH) who were treated with pegcetacoplan, an investigational, targeted C3 therapy.

Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.

- Commits to Non-GAAP Net Income Margin Targets of ~25% for FY 2023 and ~30% for FY 2024, Reflecting Rigorous Expense Management, Expected Revenue Growth and Commitment to Shareholder Value Creation - - Announces Potential Monetization of Non-Core Assets and Reiterates Commitment to Exploring Strategic Collaborations Around ALKS 4230 - - Two New Independent Directors Appointed and Board Refreshment Program to Continue -